Effectiveness of prophylaxis against tuberculosis in patients infected with HIV
Abstract
Introduction. Prophylaxis against tuberculosis has been recognized as important for preventing clinical forms of tuberculosis, mainly in HIV positive patients. However, in countries with high tuberculosis prevalence, prophylaxis application and effectiveness remains controversial.Objective. Effectiveness was established for two prophylaxis regimens -isoniazid treatment for nine months and pirazinamid/rifampin for 60 days.
Materials and methods. Two cohort groups of patients diagnosed with HIV/AIDS were compared. One consisted of 131 volunteer patients, who received one of the two prophylactic regimens - pirazinamid/rifampin or isoniazid. The tuberculosis treatment drugs were self-administered and
independent of tuberculin response tests. The second group consisted of 200 patients selected from the records of a HIV/AIDS control program. Follow up for both groups was conducted over a two-year period through clinical records.
Results. The 2 groups were similar with respect to clinical and demographic variables. A higher proportion of patients in the control group had CD4 counts <200/ml and viral load
>100,000 copies. In the prophylactic group, 8% of patients reported adverse effects due to the drug, and one person had tuberculosis in that group (0.8%). Ten persons in the control group contracted tuberculosis (5%) [RR=0.15, 95%CI 0.02-1.18, p=0.07]. The prophylaxis protective level was calculated to be 80%, after taking into account CD4, viral load, and effective antiretroviral therapy.
Conclusion. The prophylaxis against tuberculosis was effective in HIV positive patients, independently of the immune status, viral load, and highly effective antiretroviral therapy.
Downloads
References
1. Aukhtun OI, Golanov VS, Berezin NG, Kirbiat'eva EN. Clinical picture and treatment of tuberculosis in HIV-infected patients. Probl Tuberk. 2002;11:21-3.
2. Bowersox J. Short-course TB prophylaxis effective in HIV-infected individuals. NIAID AIDS Agenda. 1998; 8:4-5.
3. Charles M, Pape JW. Tuberculosis and HIV: Implications in the developing world. Curr HIV /AIDS Rep. 2006;3:139-44.
4. Cahn P, Perez H, Ben G, Ochoa C. Tuberculosis and HIV: a partnership against the most vulnerable. J Int Assoc Physicians AIDS Care. 2003;2:106-23.
5. Aït KN, Enarson D, Billo N. The epidemiology of tuberculosis and of the resistance to antitubercular agents. Rev Mal Respir. 1997;14(Suppl.5):S8-18.
6. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293:2776-84.
7. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005;19:1113-24.
8. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94-102.
9. DíazGranados CA, Alvarez C, Prada G. Guía para el manejo de VIH/SIDA basada en la evidencia. Colombia. Bogotá: Fundación para la Investigación y el Desarrollo de la Salud y la Seguridad Social-FEDESALUD; 2005.
10. Center for Healthcare Environmental Management. CDC publishes flexible draft guidelines on tuberculosis control. Health Hazard Manage Monit. 2005;18:1-7.
11. Smith PG. Epidemiological methods to evaluate vaccine efficacy. Br Med Bull. 1988;44:679-90.
12. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIVtuberculosis coinfected populations. Proc Natl Acad Sci USA. 2006;103:7042-7.
13. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-72.
14. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Perez-Tascon M, Miralles P, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med. 1993;119:194-8.
15. Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Longterm effect on development of tuberculosis and survival. Arch Intern Med. 1997;157:1729-34.
16. Moreno S, Podzamczer D, Blazquez R, Iribarren JA, Ferrer E, Reparaz J, et al. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS. 2001;15:1185-7.
17. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171.
18. Pape JW. Tuberculosis and HIV in the Caribbean: approaches to diagnosis, treatment, and prophylaxis. Top HIV Med. 2004;12:144-9.
19. Gálvez Hermoso C, Blanco Quintana F, del Amo Valero J, Diez Ruiz-Navarro M, Soriano Vazquez V, Gonzalez Lahoz J. Effect of antiretroviral treatment and prophylaxis for opportunistic infections on survival of patients with AIDS. Rev Clin Esp. 2000;200:187-92.
20. Bandyopadhyay T, Murray H, Metersky ML. Costeffectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest. 2002;121:1771-5.
21. García I, Merchán A, Chaparro PE, López LE. Panorama de la coinfección tuberculosis/VIH en Bogotá, 2001. Biomédica. 2004;24 (Suppl.1):132-7.
22. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006,42:464-9.
23. Gordin F. Short-term tuberculosis prophylaxis is effective in persons with HIV. Am Fam Physician. 1998;58:948.
24. Ronge R. What does tuberculosis prophylaxis bring in HIV infections? Dtsch Med Wochenschr. 1999;124:A8-9.
25. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients
with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004;48:4473-5.
26. Lawn SD, Wood R. Tuberculosis control in South Africa -will HAART help? S Afr Med J. 2006;96:502-4.
27. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12:744-51.
Some similar items:
- Constanza Pardo, Ricardo Cendales, Survival analysis of cervical cancer patients , Biomedica: Vol. 29 No. 3 (2009)
- Raúl Murillo, Ricardo Cendales, Carolina Wiesner, Marion Piñeros, Sandra Tovar, Effectiveness of cytology-based cervical cancer screening in the Colombian health system , Biomedica: Vol. 29 No. 3 (2009)
- Sandra Lorena Girón, Julio César Mateus, Fabián Méndez, Impact of an open waste disposal site on the occurrence of respiratory symptoms and on health care costs of children , Biomedica: Vol. 29 No. 3 (2009)
- José Joaquín Carvajal, Ligia Inés Moncada, Mauricio Humberto Rodríguez, Ligia del Pilar Pérez, Víctor Alberto Olano, Characterization of Aedes albopictus (Skuse, 1894) (Diptera:Culicidae) larval habitats near the Amazon River in Colombia , Biomedica: Vol. 29 No. 3 (2009)
- Andrés Páez, Gloria Rey, Carlos Agudelo, Alvaro Dulce, Edgar Parra, Hernando Díaz-Granados, Damaris Heredia, Luis Polo, Outbreak of urban rabies transmitted by dogs in Santa Marta, northern Colombia , Biomedica: Vol. 29 No. 3 (2009)
- Patricia Escobar, Katherine Paola Luna, Indira Paola Hernández, César Mauricio Rueda, María Magdalena Zorro, Simon L. Croft, In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole , Biomedica: Vol. 29 No. 3 (2009)
- Gustavo Pradilla, Julio César Mantilla, Reynaldo Badillo, Human rabies encephalitis by a vampire bat bite in an urban area of Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Mauricio Beltrán, María Cristina Navas, María Patricia Arbeláez, Jorge Donado, Sergio Jaramillo, Fernando De la Hoz, Cecilia Estrada, Lucía del Pilar Cortés, Amalia de Maldonado, Gloria Rey, Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Rosa Magdalena Uscátegui, Adriana M. Correa, Jaime Carmona-Fonseca, Changes in retinol, hemoglobin and ferritin concentrations in Colombian children with malaria , Biomedica: Vol. 29 No. 2 (2009)
- Claudia M.E. Romero-Vivas, Luis Eduardo Castro, Lila Visbal, Ana María Santos, Esther Díaz, Cutaneous myiasis by Cochliomyia hominivorax (Coquerel) (Díptera Calliphoridae) in Hospital Universidad del Norte, Soledad, Atlántico , Biomedica: Vol. 29 No. 1 (2009)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
